# Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

> **NCT05527821** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 36 (estimated)

## Conditions studied

- Unresectable Advanced Solid Tumors
- Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Sintilimab
- **RADIATION:** Short course radiotherapy

## Key facts

- **NCT ID:** NCT05527821
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-30
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527821, "Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05527821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*